• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health Product Image

Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health

  • Published: May 2011
  • Region: Global
  • 67 Pages
  • Spectra Intelligence

FEATURED COMPANIES

  • AstraZeneca
  • Ferring
  • Johnson & Johnson
  • Merck & Co
  • Merck & Co
  • Merck Serono
  • MORE

Provides analysis of over ten key marketed products and indentifies over 40 R&D candidates in preclinical to clinical stages of development.

The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.

In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Key findings of the report include
- The READ MORE >

Executive Summary
Report Highlights

Objectives of the Report
1. Contraception and Infertility: Market Snapshot
Market data synopsis - contraception and infertility
1.1 Reproductive Health Market Overview
1.2 Market Analysis for Contraception and Infertility
1.2.1 Contraception
1.2.2 Infertility

2. Product Market for Hormonal Contraception
2.1 Contraceptive Formulations
2.2 Combined Estrogen-Progestogen Contraceptives
2.3 Progestogen-Only Contraceptives
2.4 Product Market for Hormonal Contraceptives
2.4.1 Bayer Healthcare Pharmaceuticals
2.4.1.1 Key Product and Portfolio Review
2.4.1.2 Pipeline Focus
Contraceptive Patch
Intrauterine device
2.4.1.3 Sales Estimates and Product Market Outlook
2.4.2 Johnson & Johnson
2.4.2.1 Key Product and Portfolio Review
2.4.2.2 Sales Forecasts and Product Market Outlook
2.4.3 Merck & Co
2.4.3.1 Key Product and Portfolio Review
2.4.3.2 Sales Estimates and Product Market Outlook
2.4.4 Pfizer
2.4.4.1 Key Product and Portfolio Review
2.4.4.2 Sales Estimates and Product Market Outlook
2.4.5 Teva Pharmaceutical Industries
2.4.5.1 Key Product and Portfolio Review
2.4.5.2 Pipeline Focus
2.4.5.3 Sales Estimates and Product Market Outlook
Generics Focus - Watson Pharmaceuticals
2.5 Future Considerations and Outlook for the Contraceptive Product Market

3. Product Market for Infertility Drugs
3.1 Overview for Infertility Drugs
3.2 Pharmacotherapies for Infertility
Mechanism of Action of Infertility Pharmacotherapeutics
3.3 Product Market for Infertility Drugs
3.3.1 AstraZeneca
3.3.1.1. Key Product Review
3.3.1.2 Sales Estimates and Product Market Outlook
3.3.2 Ferring
3.3.2.1 Key Product and Portfolio Review
3.3.2.2. Sales Estimates and Product Market Outlook
3.3.3 Merck & Co
3.3.3.1 Key Product and Portfolio Review
3.3.4 Merck Serono
3.3.4.1 Key Product and Portfolio Review
3.3.4.2 Sales Estimates and Product Market Outlook
3.4 Market Outlook for Infertility Pharmacotherapeutics

4. Research and Development in Reproductive Health
4.1 Female Oral Contraception
4.1.1 Transdermal/Transmucosal Contraceptives
4.1.2 Implantable/Injectable Contraceptives
4.2 Male Contraception
4.3 Contraception - Research and Development Overview
4.4 Infertility Drugs in Research and Development
4.4.1 Female Infertility
4.4.2 Male Infertility
6.3.2.1 Infertility - Research and Development Overview

Reference Sources

List of Tables
Research Methodology
Table 1.1 Estimated Global Sales (US$m) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
Table 2.1 Selection of Hormonal Contraceptives Segmented by Formulation and Delivery Route, 2011
Table 2.2 Bayer's Hormonal Contraceptive Product Portfolio, 2011
Table 2.3 Bayer`s Pipeline Contraceptive Candidates, 2011
Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Bayer's Leading Hormonal Contraceptive Products, 2011-2018
Table 2.5 Johnson & Johnson`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.6 Estimated Sales (US$m) and Annual Growth (%) of Johnson & Johnson`s Leading Hormonal Contraceptive Products, 2011-2018
Table 2.7 Merck & Co's Hormonal Contraceptive Product Portfolio, 2011
Table 2.8 Estimated Sales (US$m) and Annual Growth (%) of Merck & Co's Leading Hormonal Contraceptive Products, 2011-2018
Table 2.9 Pfizer`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.10 Estimated Sales (US$m) and Annual Growth (%) of Pfizer`s Leading Hormonal Contraceptive Products, 2011-2018
Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011 (continued)
Table 2.12 Estimated Sales (US$m) and Annual Growth (%) of Teva`s Leading Hormonal
Table 3.1 Pharmacotherapies for Infertility, 2011
Table 3.2 Ferring`s Infertility Product Portfolio, 2011
Table 3.3 Estimated Global Sales (US$m) and Annual Growth (%) of Ferring`s Infertility Products, 2011-2018
Table 3.4 Merck & Co.`s Hormonal Infertility Product Portfolio, 2011
Table 3.5 Estimated Global Sales (US$m) and Annual Growth (%) of Merck & Co.'s Hormonal Infertility Products, 2011-2018
Table 3.6 Merck Serono`s Hormonal Infertility Product Portfolio, 2011
Table 3.7 Estimated Global Sales (US$m) and Annual Growth (%) of Merck Serono`s Hormonal Infertility Products, 2011-2018
Table 4.1 Female Oral Contraceptives in Development, 2011
Table 4.1 Female Oral Contraceptives in Development, 2011 (continued)
Table 4.2 Transdermal/Transmucosal Female Contraceptives in Development, 2011
Table 4.3 Implantable/Injectable Female Contraceptives in Development, 2011
Table 4.4 Male Contraceptives in Development, 2011
Table 4.5 Drugs in Development for Female Infertility, 2011
Table 4.6 Drugs in Development for Male Infertility, 2011

List of Figures
Figure 1.1 Estimated Sales (US$m) and Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
Figure 1.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2011 & 2018
Figure 2.1 Global Revenue Trends for Bayer's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.2 Global Revenue Trends for Johnson & Johnson's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.3 Global Revenue Trends for Merck & Co's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.4 Global Product Sales for Pfizer's Hormonal Contraceptive Franchise, 2005-2010
Figure 2.5 Global Sales Trends of Teva's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.6 Leading Hormonal Contraceptive Products by Sales Revenue (US$m), 2011 (estimated)
Figure 3.1 Global Sales Trends of Merck & Co.'s Leading Hormonal Infertility Products, 2005-2010
Figure 3.2 Global Sales Trends of Merck Serono's Leading Hormonal Infertility Products,
Figure 3.3 Leading Hormonal Infertility Products by Sales Revenue (US$m), 2011 (estimated)

Female hormonal contraceptives market forecast to hit US$7.2 in 2014 says report

But, post 2014, the market value will fall as generics come to market.

The market for female hormonal contraceptives is estimated to grow by 5% from $6.9bn in 2011 to $7.2bn by 2014, says a new report from URCH Publishing. However, after 2014, the market value will decline by over 19% to $5.5bn by 2018 as cheaper generics offset premium brands and innovative products.

The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 says that market leaders for female contraception include Bayer with annual revenues of $3bn, followed by Teva at $1.2bn, and Merck & Co. with $1bn in annual sales. High-revenue products include Bayer’s Yasmin/Yaz/Yasminelle franchise; Mirena, Merck & Co.’s NuvaRing; and Teva’s Ocella and Sprintec product lines, which collectively account for US$3.5bn in annual revenues.

Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.

The report notes that “double-digit growth will be based on the introduction of sophisticated next-generation products along with prospects for male contraception, but this has yet to prove successful in long-term clinical trials.” Currently, there are over 40 pipeline candidates for female and male contraception.

The 67 page report analyses current product markets, research and development themes, and company activities within the field. The report evaluates sales trends and pharmacological innovation, and provides a detailed account of the newly approved and pipeline prospects that are anticipated to expand the market substantially over the next decade. Updates on novel drug development for male contraception and male infertility are detailed in addition to the commercial opportunities based on unmet needs.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.

- Bayer Healthcare Pharmaceuticals
- Johnson & Johnson
- Merck & Co
- Pfizer
- Teva Pharmaceutical Industries
- AstraZeneca
- Ferring
- Merck & Co
- Merck Serono

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos